Product Images Rubraca

The text provided seems to be a mix of random characters and numbers, with a mention of two drugs, Rubraca and Placebo, and the median number of months. It is not enough for me to generate a useful description.*

The text appears to be a table showing the number of events of Avrisk for Rubraca and Placcbo in a clinical trial. It also contains some numeric values that seem to be related to the duration of the study but the context is not clear.*

This appears to be a chart or graph displaying data from a clinical trial of a medicine called Rubraca compared to a placebo. The chart shows a horizontal axis of months and a vertical axis of percentages. The percentages represent the "range" of patients experiencing a certain outcome, likely related to efficacy or side effects. However, it is difficult to determine the specifics of the trial and the meaning of the data without additional context.*

This is a description of the usual dosage, storage, and relevant information for Rucaparib, a medication distributed by Clovis Oncology, Inc. The prescribing information should be used to determine the appropriate dosage. The tablets should be stored at a temperature between 20°C and 25°C (68°F and 77°F), with excursions between 15°C and 30°C (59°F and 86°F) permitted as long as they meet the USP Controlled Room Temperature requirements. Each tablet contains 344 mg rucaparib camsyate equivalent to 200 mg rucaparib. The medication is made in Switzerland, and the NDC code is 69660-201-91. The tablets are only available with a prescription and should be kept out of the reach of children.*

This is a description of the usual dosage and storage instructions for Rubraca (rucaparib) tablets. The dosage information can be found in the prescribing information. The tablets should be stored between 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C and 30°C (59°F and 86°F), as indicated by the USP Controlled Room Temperature. The tablets come in 250 mg and the bottle contains 60 tablets. This medication should be kept out of reach of children. It is distributed by Clovis Oncology, Inc. and made in Switzerland.*

This is the prescribing information for Rubraca (rucaparib) tablets. The text provides details on the usual dosage of this medication and storage instructions. It also includes the distributor's information, manufacturing location, tablet composition, and unique identification code. The medication is available only with a prescription and should be kept out of reach of children.*